Literature DB >> 24006136

Anti-leishmania infantum IgG antibody avidity in visceral leishmaniasis.

Monique Gomes Salles Tiburcio1, Laís Anversa, Kelly Aparecida Kanunfre, Antonio Walter Ferreira, Virmondes Rodrigues Júnior, Luciana de Almeida Silva.   

Abstract

IgG avidity tests are used to discriminate acute from chronic infections. There are few reports on the IgG avidity profile of patients with visceral leishmaniasis (VL). This study investigated the anti-Leishmania IgG avidity in patients with classic VL (n = 10), patients showing clinical cure after treatment (n = 18), and asymptomatic subjects with at least one positive Leishmania test (n = 20). All subjects were from areas in Brazil where VL is endemic. Serum samples were collected from each subject on two different occasions. IgG avidity was evaluated by Western blotting. The proportion of high-avidity antibodies was higher in all samples from patients with classic VL. In contrast, low-avidity antibodies predominated in subjects with a history of VL, including 13 cases (72.2%) in the first assessment and 14 (77.8%) in the second. Fifteen (75%) of the asymptomatic subjects presented a predominance of low-avidity antibodies in the first assessment, and the frequency of high-avidity antibodies increased over time in seven subjects (35%) of this group. Antibodies against the 14- and/or 16-kDa antigen fraction were detected in the first assessment in all patients with classic VL, in 10 (55.5%) treated patients, and in 10 (50%) asymptomatic subjects. These were high-avidity antibodies in most cases. In the asymptomatic group, an increase in IgG avidity against the 14- and/or 16-kDa antigen fraction was observed in three cases (15%). The results indicate distinct responses in infected and asymptomatic subjects, probably associated with the length of time after infection. In this respect, IgG avidity tests represent a new approach to better characterize asymptomatic VL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24006136      PMCID: PMC3837788          DOI: 10.1128/CVI.00367-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  27 in total

1.  Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up.

Authors:  S M Jeronimo; M J Teixeira; A d Sousa; P Thielking; R D Pearson; T G Evans
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Use of the polymerase chain reaction for the diagnosis of asymptomatic Leishmania infection in a visceral leishmaniasis-endemic area.

Authors:  Luciana Almeida Silva; Héctor Dardo Romero; Aline Fagundes; Nédia Nehme; Otávio Fernandes; Virmondes Rodrigues; Roberto Teodoro Costa; Aluízio Prata
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2013 Mar-Apr       Impact factor: 1.846

Review 4.  Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human.

Authors:  Grégory Michel; Christelle Pomares; Bernard Ferrua; Pierre Marty
Journal:  Acta Trop       Date:  2011-06-06       Impact factor: 3.112

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA.

Authors:  A E Harith; A H Kolk; P A Kager; J Leeuwenburg; F J Faber; R Muigai; S Kiugu; J J Laarman
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

8.  Prevalence of Trypanosoma cruzi and Leishmania chagasi infection and risk factors in a Colombian indigenous population.

Authors:  A Corredor Arjona; C A Alvarez Moreno; C A Agudelo; M Bueno; M C López; E Cáceres; P Reyes; S Duque Beltran; L E Güaldron; M M Santacruz
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1999 Jul-Aug       Impact factor: 1.846

9.  The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection.

Authors:  Regina F S Braz; Eliana T Nascimento; Daniella R A Martins; Mary E Wilson; Richard D Pearson; Steven G Reed; Selma M B Jeronimo
Journal:  Am J Trop Med Hyg       Date:  2002-10       Impact factor: 2.345

10.  Inaccuracy of enzyme-linked immunosorbent assay using soluble and recombinant antigens to detect asymptomatic infection by Leishmania infantum.

Authors:  Elizabeth Castro Moreno; Andréa Vieira Gonçalves; Anderson Vieira Chaves; Maria Norma Melo; José Roberto Lambertucci; Antero Silva Ribeiro Andrade; Deborah Negrão-Corrêa; Carlos Mauricio de Figueiredo Antunes; Mariângela Carneiro
Journal:  PLoS Negl Trop Dis       Date:  2009-10-20
View more
  1 in total

1.  Syk inhibitors interfere with erythrocyte membrane modification during P falciparum growth and suppress parasite egress.

Authors:  Antonella Pantaleo; Kristina R Kesely; Maria Carmina Pau; Ioannis Tsamesidis; Evelin Schwarzer; Oleksii A Skorokhod; Huynh D Chien; Marta Ponzi; Lucia Bertuccini; Philip S Low; Francesco M Turrini
Journal:  Blood       Date:  2017-06-20       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.